Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 261.69M P/E - EPS this Y -248.40% Ern Qtrly Grth -
Income -46.48M Forward P/E -5.96 EPS next Y -4.60% 50D Avg Chg -20.00%
Sales 2.71M PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 1.69 EPS next 5Y - 52W High Chg -79.00%
Recommedations 1.80 Quick Ratio 20.87 Shares Outstanding 38.83M 52W Low Chg 88.00%
Insider Own 5.08% ROA - Shares Float 37.12M Beta 2.31
Inst Own 20.64% ROE - Shares Shorted/Prior 2.97M/3.21M Price 6.74
Gross Margin 100.00% Profit Margin - Avg. Volume 1,237,606 Target Price 31.67
Oper. Margin -1,791.78% Earnings Date - Volume 424,091 Change -2.88%
Oramed Pharmaceuticals Inc. News
09/13/22 Oramed Oral Insulin Shows Evidence For NASH Treatment
09/13/22 Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
09/06/22 Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
08/25/22 ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts
08/01/22 We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
06:55 AM Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
07/12/22 Why Oramed Pharmaceuticals Stock Is On Fire Today
07/11/22 Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
07/08/22 Why Oramed Pharmaceuticals Stock Rocketed Higher Today
07/07/22 Oramed Letter to Shareholders
06/01/22 Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
05/24/22 Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
05/18/22 Oramed to Present at H.C. Wainwright Global Investment Conference
05/10/22 Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week
05/03/22 Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
04/27/22 ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing
04/05/22 Oramed Granted NASH Patent in Europe
04/04/22 Oramed Appoints Yadin Rozov to its Board of Directors
03/29/22 Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

ORMP Chatroom

User Image macroaxis Posted - 6 hours ago

Oramed Pharma ( $ORMP ) ALMOST MIRRORS THE MARKET with average… https://www.macroaxis.com/stock/ORMP/Oramed-Pharma #stocks #news #wallstreet

User Image macroaxis Posted - 6 hours ago

$ORMP - Next fiscal year end is on 23rd of November 2022. Oramed Pharma Separating Lines… https://www.macroaxis.com/stocks/Pattern-Recognition/Separating-Lines/ORMP

User Image DejuanWalker Posted - 1 day ago

$OPGN $ORMP GOOD QUESTION!! ↳ Why are you paying to be in a Trading Room? FREE Trading Room via (Google Search)⟶ 𝐟𝐫𝐞𝐞𝐚𝐥𝐞𝐫𝐭.𝐩𝐰

User Image macroaxis Posted - 2 days ago

Oramed Pharma ( $ORMP ) buy or sell recommendation is STRONG SELL https://www.macroaxis.com/stock/ORMP/Oramed-Pharma

User Image macroaxis Posted - 2 days ago

$ORMP - Next fiscal year end is on 23rd of November 2022. Gravestone Doji event detected… https://www.macroaxis.com/stocks/Pattern-Recognition/Gravestone-Doji/ORMP

User Image macroaxis Posted - 2 days ago

$ORMP - Puts open interest is shifting for Oramed Pharma this week https://www.macroaxis.com/stock-options/ORMP/Oramed-Pharma?utm_source=dlvr.it&utm_medium=stocktwits

User Image VetforVets Posted - 2 days ago

$ORMP Nadav said there was a hiccup with the lab for the Covid results but should get them sooner than later. Is Q3 still on the table.

User Image Schwarzy Posted - 2 days ago

$VXRT $ORMP The current vaccines are worthless, we need better ones: VXRT: Our vaccine is the best World: Great, when can you deliver? VXRT: Ah, it's not ready yet World: What? So when will it be ready? VXRT: We're in phase 2, need a year or two, tops. World: Fine, guess it's worth waiting for a highly effective vaccine. VXRT: Well, about that, at least 50% had a somewhat good response. World: Are you shitting me? ORMP: Our vaccine has triple proteins and is superior. World: Thank god, can you take our orders? ORMP: Well, it's not ready yet. World: Are you also in phase 2? ORMP: Ehhh, we're going to conclude a clinical trial any day now World: Oh, fuck me.

User Image FutureStonksToWatch Posted - 3 days ago

$ORMP down 4.67% for the day, up 4.47% in the after hours... What to do what to do...

User Image Hazeperez11 Posted - 3 days ago

$ORMP Come on down to papa!.

User Image Hazeperez11 Posted - 3 days ago

$ORMP Whats everyone's average here?.

User Image vittoriacolonna Posted - 3 days ago


User Image SamTheMan2 Posted - 3 days ago

$ORMP I shipped out a few extra USB‘s to Nadav to help out with the transfer of data on the oral vaccine trials. They probably didn’t get it yet that is why I’m guessing we are having delays. Sorry guys next time I’ll overnight them! 😉

User Image NickBFinanc Posted - 4 days ago

$ORMP * Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. * Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively. * An oral GLP-1 drug is being developed in the pipeline to treat patients with Type 2 Diabetes. * The global Type 2 Diabetes market opportunity could double to $58.7 billion by 2025.

User Image Schwarzy Posted - 4 days ago

$ORMP What the hell was that? A computer glitch?

User Image Fmello Posted - 4 days ago

$ORMP - Tried to make an Oramed post on th Reddit sub /r/WallStreetBets and discovered that the mods do not allow a stock with market cap under 500 million to be discussed.

User Image OffComesTheShirt Posted - 4 days ago

$ORMP Added 100 shares at 7.40 and sold Feb 10c for 2.55. Net cost on shares is 4.85 so great way to average down!

User Image jacckkmm Posted - 4 days ago


User Image Liliy Posted - 5 days ago

$ORMP https://seekingalpha.com/article/4542234-oramed-oral-insulin-for-type-2-diabetes-become-reality?mailingid=29117924&messageid=2800&serial=29117924.2022&source=email_2800&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=29117924.2022

User Image Jaymb58 Posted - 5 days ago

$ORMP I bought today... added 800 shares

User Image Schwarzy Posted - 5 days ago

$ORMP This will be my second Jewish new year holding this stock. Last year it was the delay with the Israeli Covid trial (may it rest in peace). And this year there is a delay in the south African lab. I'm starting to hate Rosh Hashana ;-)

User Image NickBFinanc Posted - 6 days ago

$ORMP price targets (via quantisnow.com) $20.00 (+161%) - Cantor Fitzgerald $32.00 (+318%) - HC Wainwright & Co. $35.00 (+357%) - Aegis Capital $30.00 (+292%) - Canaccord Genuity

User Image macroaxis Posted - 6 days ago

$ORMP - Oramed Pharma has a frail financial position… https://www.macroaxis.com/stock-analysis/ORMP/Oramed-Pharma #insidertrading #stocks #fintechnews

User Image TravisHaze Posted - 6 days ago

$ORMP Recent price targets look good from reputable sources. https://quantisnow.com/ratings

User Image cctranscripts Posted - 6 days ago

Amendments to Articles of Incorporation or https://www.conferencecalltranscripts.com/summary/?id=11311860 $ORMP

User Image Last10K Posted - 6 days ago

$ORMP just filed with the SEC a Bylaw Change and a Financial Exhibit https://last10k.com/sec-filings/ormp/0001213900-22-057036.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ormp

User Image Quantisnow Posted - 6 days ago

$ORMP 📜 Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits https://quantisnow.com/i/3428026?utm_source=stocktwits 45 seconds delayed.

User Image risenhoover Posted - 6 days ago

$ORMP / Oramed Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2022 https://fintel.io/sf/us/ormp?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image fla Posted - 6 days ago

$ORMP [15s. delayed] filed form 8-K on September 19, 17:05:12 https://s.flashalert.me/ZGc4A

User Image stockilluminati Posted - 6 days ago

$ORMP https://www.stockilluminati.com/ormp/filings.php - Oramed Pharmaceuticals Inc. - Common Stock files form 8-K today, check out the details.

Analyst Ratings
Aegis Capital Buy May 16, 22
Cantor Fitzgerald Overweight Feb 18, 22
HC Wainwright & Co. Buy Nov 30, 21
HC Wainwright & Co. Buy Nov 29, 21
Aegis Capital Buy Nov 2, 21
Canaccord Genuity Buy Jul 29, 21
Aegis Capital Buy Jun 8, 21
Canaccord Genuity Buy Apr 20, 21
National Securities Corporation Buy Feb 9, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mayer Arie Director Director Nov 01 Sell 25.60 3,000 76,800 05/10/22
RAKIN KEVIN Director Director Mar 21 Sell 9.4096 10,000 94,096 46,661 03/22/22
RAKIN KEVIN Director Director Feb 17 Option 4.8 6,667 32,002 59,671 02/22/22